Sofinnova Venture Partners IX, L.P. 4
4 · Galera Therapeutics, Inc. · Filed Nov 12, 2019
Insider Transaction Report
Form 4
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2019-11-12−9,090,909→ 0 total→ Common Stock (1,797,843 underlying) - Conversion
Series C Preferred Stock
2019-11-12−2,709,659→ 0 total→ Common Stock (535,869 underlying) - Conversion
Common Stock
2019-11-12+2,333,712→ 2,333,712 total - Purchase
Common Stock
2019-11-12$12.00/sh+750,000$9,000,000→ 3,083,712 total
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.
- [F2]The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein.